Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note published on Thursday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Up 5.3 %

Evoke Pharma stock opened at $4.53 on Thursday. The company has a fifty day simple moving average of $4.49 and a 200-day simple moving average of $5.01. The firm has a market capitalization of $6.75 million, a price-to-earnings ratio of -0.41 and a beta of 0.15. Evoke Pharma has a 52-week low of $3.54 and a 52-week high of $12.32.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.94) EPS for the quarter. The business had revenue of $2.65 million during the quarter. Evoke Pharma had a negative net margin of 71.32% and a negative return on equity of 308.49%.

Institutional Trading of Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new stake in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned about 1.42% of Evoke Pharma at the end of the most recent quarter.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.